TIGATUZUMAB
UNII 237GB6IDKO

Substance Identification & Data

This profile provides standardized clinical and technical data for Tigatuzumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 237GB6IDKO.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 918127-53-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

237GB6IDKO

CAS Registry Number

918127-53-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TIGATUZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C62482

National Cancer Institute reference terminology for clinical and research data.

INN ID

8979

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Tigatuzumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TIGATUZUMAB

Common Names & Synonyms

ANTI-DR5 MOAB

ANTI-TRAIL-R2 MOAB

TIGATUZUMAB [INN]

TIGATUZUMAB [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN CYTOKINE RECEPTOR DR5 (DEATH RECEPTOR 5)) (HUMAN-MOUSE MONOCLONAL TRA-8 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL TRA-8 .KAPPA.-CHAIN, DIMER

SYS